APRE stock forecast
Our latest prediction for Aprea Therapeutics, Inc.'s stock price was made on the July 7, 2020 when the stock price was at 34.00$.
In the short term (2weeks), APRE's stock price should underperform the market by -3.42%. During that period the price should oscillate between -12.35% and +10.68%.
In the medium term (3months), APRE's stock price should underperform the market by -6.10%. During that period the price should oscillate between -41.38% and +32.51%.Get email alerts
Create a solid portfolio with APRE
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.61$ per share.
The book value per share is 5.90$
Three months stock forecastJuly 7, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|